- A clinical trial at Memorial Sloan Kettering Cancer Center achieved complete remission in 14 patients with rectal cancer using immunotherapy.
- The trial used dostarlimab, a single immunotherapy drug, without surgery, chemotherapy, or radiation.
- Patients remained cancer-free for a median of 25 months, with some approaching three years in remission.
- Mismatch repair-deficient rectal cancers have a unique vulnerability to immunotherapy due to genetic mutations.
- This breakthrough suggests immunotherapy alone may eradicate certain cancers, challenging conventional treatment paradigms.
In a medical breakthrough that could redefine the future of cancer care, a small clinical trial has achieved what oncologists once considered nearly impossible: complete remission in every patient with a specific form of rectal cancer, without surgery, chemotherapy, or radiation. The trial, conducted at Memorial Sloan Kettering Cancer Center, involved 14 patients with locally advanced mismatch repair-deficient rectal adenocarcinoma — a rare but aggressive form of bowel cancer. After receiving a single immunotherapy drug, dostarlimab, every three weeks for six months, all 14 patients showed no detectable tumors at the end of treatment and remained cancer-free for a median follow-up of 25 months, with some now approaching three years in remission. These unprecedented results, published in The New England Journal of Medicine in 2023, suggest that immunotherapy alone may eradicate certain cancers, challenging decades of conventional treatment paradigms.
\n
The Rise of Immunotherapy in Precision Oncology
\n
This trial represents a pivotal moment in the evolution of precision oncology, where treatments are tailored to the genetic profile of a patient’s tumor. Mismatch repair-deficient (dMMR) cancers, which account for about 5% of rectal cancers, have a unique vulnerability: they accumulate numerous genetic mutations, making them highly visible to the immune system. Dostarlimab, a PD-1 inhibitor developed by GlaxoSmithKline, works by releasing the brakes on immune cells, enabling them to recognize and destroy cancer cells. Unlike traditional treatments that indiscriminately attack rapidly dividing cells — damaging healthy tissue in the process — immunotherapy harnesses the body’s natural defenses. The fact that this approach not only worked but achieved 100% clinical response without the debilitating side effects of chemotherapy or the permanence of colostomy surgery has stunned the oncology community.
\n
How the Trial Was Conducted
\n
The phase II trial, led by Dr. Luis A. Diaz Jr., enrolled patients with stage II or III dMMR rectal cancer who had not yet undergone standard treatment. Each participant received dostarlimab infusions every three weeks for six months, after which they were evaluated using MRI, endoscopy, and biopsy. Remarkably, every patient showed a complete clinical response — no signs of residual tumor. Instead of proceeding to chemoradiation and surgery, typically the standard of care, patients were monitored closely. None experienced recurrence during the follow-up period, and none required invasive procedures. The trial did not include a control group, limiting statistical generalization, but the consistency of results is unprecedented. The treatment was well tolerated, with only mild side effects such as fatigue and rash reported. Given the trial’s success, researchers have expanded enrollment to confirm results in a larger cohort.
\n
Why This Success Wasn’t Predicted
\n
Historically, rectal cancer has been treated with a multimodal approach: radiation, chemotherapy, and surgery — often resulting in long-term complications like bowel dysfunction, infertility, and sexual health issues. The idea that a single drug could replace this entire regimen seemed implausible. However, the dMMR subtype’s high tumor mutational burden creates a microenvironment ripe for immune attack. Prior success with PD-1 inhibitors in dMMR colorectal cancers that had metastasized — such as the FDA approval of pembrolizumab — provided a foundation, but applying immunotherapy in the early, localized setting was uncharted territory. Experts speculate that intervening before the tumor establishes immune evasion mechanisms may be key. As Dr. Diaz noted in an interview with The New York Times, \”We’ve never seen anything like this in medicine — a cure for a cancer with a single drug, with no surgery or chemo.\”
\n
Implications for Patients and Healthcare Systems
\n
If validated in larger trials, this approach could transform care for thousands of patients annually. In the U.S. alone, about 50,000 new rectal cancer cases are diagnosed each year, with roughly 2,500 being dMMR. Avoiding surgery and chemotherapy would not only improve quality of life but also reduce healthcare costs and hospital burden. Colostomy reversal surgeries, rehabilitation, and long-term management of treatment side effects cost tens of thousands of dollars per patient. Moreover, the psychological toll of cancer treatment — anxiety, depression, sexual dysfunction — could be significantly reduced. However, challenges remain: dostarlimab is expensive, costing approximately $11,000 per infusion, and access to genetic testing for dMMR status is not universal. Equitable implementation will require policy changes and expanded screening protocols.
\n
Expert Perspectives
\n
While the results are celebrated, some oncologists urge caution. Dr. Cathy Eng of Vanderbilt-Ingram Cancer Center told Reuters that \”longer follow-up is essential to confirm durability.\” Others point out that dMMR cancers are more common in younger patients with Lynch syndrome, raising questions about genetic counseling and surveillance. Meanwhile, immunotherapy skeptics warn of potential resistance mechanisms emerging over time. Still, the consensus is that this trial marks a watershed moment — not just for rectal cancer, but for solid tumors broadly. Researchers are already planning trials for dMMR cancers in the pancreas, prostate, and endometrium.
\n
Looking ahead, the critical questions are whether these results will hold in a larger, randomized trial and if similar success can be replicated in other cancer types. Scientists are also investigating biomarkers to predict which patients will respond best. The FDA has granted dostarlimab breakthrough therapy designation, accelerating its review. If approved for early-stage dMMR rectal cancer, it could become the first immunotherapy to replace surgery. As precision oncology advances, this trial stands as a beacon of what’s possible: a future where cancer is not just managed, but cured — quietly, without scalpel or radiation, by awakening the body’s own defenses.
Source: Scitechdaily